Investigational drug · Phase 3
Telitacicept
Also called: RC18, RC18-L
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for CTD-ILD, Primary Sjogren's Disease, Sjögren's Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
57
Any phase or sponsor naming "Telitacicept"
First trial start
2023
Mar 28, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Telitacicept", any sponsor or status.
Conditions studied
As listed on its trial records.
- CTD-ILD
- Primary Sjogren's Disease
- Sjögren's Disease
- Generalized Myasthenia Gravis
- Myasthenia Gravis, Ocular
- Immunoglobulin A Nephropathy (IgAN)
- Complement 3 Glomerulopathy (C3G)
- IC-MPGN
- Primary IgA Nephropathy
- Myasthenia Gravis, Generalized
Approved drugs for the same conditions: Myasthenia gravis · IgA nephropathy · Neurology · Immunology and inflammation · Kidney and urology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "Telitacicept" as an intervention, largest first.
- A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.Pivotal-lookingCompleted
RemeGen Co., Ltd.Industry
NCT03016013 · 479 participants · Start Mar 29, 2017 · Primary completion Nov 19, 2022
Drug: Placebo plus MTX; RC18 160 mg plus MTX · For: Moderate and Severe RheumatoId Arthritis
Sites: Beijing, China
- Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid ArthritisPivotal-lookingRecruiting
Peking University People's HospitalAcademic, hospital or other
NCT07796516 · 420 participants (planned) · Start Sep 1, 2026 · Primary completion Dec 30, 2027
Drug: Telitacicept 160mg; Standard therapy · For: Difficult-to-treat Rheumatoid Arthritis; Rheumatoid Arthritis
Sites: Hefei, China; Beijing, China; Chongqing, China · 47 sites in all
- A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's SyndromePivotal-lookingCompleted
RemeGen Co., Ltd.Industry
NCT05673993 · 381 participants · Start Apr 6, 2023 · Primary completion Oct 29, 2024
Drug: Telitacicept 80 mg; Telitacicept 160 mg and 1 more · For: Primary Sjogren's Syndrome
Sites: Bengbu, China; Hefei, China; Beijing, China · 78 sites in all
- A Study of Telitacicept for IgA Nephropathy (TELIGAN)Pivotal-lookingActive, not recruiting
RemeGen Co., Ltd.Industry
NCT05799287 · 318 participants · Start Apr 28, 2023 · Primary completion Jun 2026
Drug: Telitacicept; Placebo · For: Primary IgA Nephropathy
Sites: Bengbu, China; Hefei, China; Wuhu, China · 101 sites in all
The Children's Hospital of Zhejiang University School of MedicineAcademic, hospital or other
NCT07354503 · 300 participants (planned) · Start Jan 1, 2026 · Primary completion Jun 30, 2027
Drug: This study exclusively prospectively collected clinical data from the patients and did not involve any therapeutic interventions · For: IgAVN; IgA Vasculitis
- Telitacicept for the Treatment of Connective Tissue Disease-associated ThrombocytopeniaPivotal-lookingRecruiting
Beijing HospitalGovernment (non-federal)
NCT05998759 · 296 participants (planned) · Start Dec 2, 2023 · Primary completion Dec 2025
Drug: Telitacicept; Placebo · For: Connective Tissue Diseases; Thrombocytopenia
Sites: Hefei, China; Beijing, China; Guangzhou, China · 23 sites in all
- Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung DiseasePivotal-lookingNot yet recruiting
RemeGen Co., Ltd.Industry
NCT07495033 · 260 participants (planned) · Start Apr 20, 2026 · Primary completion May 31, 2029
Drug: Telitacicept; Placebo · For: CTD-ILD
Sites: Beijing, China
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseasePivotal-lookingRecruiting
Vor BiopharmaIndustry
NCT07404865 · 250 participants (planned) · Start Feb 26, 2026 · Primary completion Dec 2028
Drug: Telitacicept; Placebo · For: Primary Sjogren's Disease
Sites: Chandler, Arizona; Flagstaff, Arizona; Glendale, Arizona · 49 sites in all
- A Single Dose Study to Investigate the Pharmacokinetics (PK) of Telitacicept Pre-filled Injection and Freeze-dried Powder Injection in Chinese Healthy SubjectsPivotal-lookingStatus unknown
RemeGen Co., Ltd.Industry
NCT06549959 · 248 participants (planned) · Start Aug 5, 2024 · Primary completion Nov 30, 2024
Drug: Telitacicept Pre-filled Injection 80mg; Telitacicept Freeze-dried powder Injection 80mg · For: Healthy
Sites: Guiyang, China; Chengdu, China; Tianjin, China
- A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's DiseasePivotal-lookingNot yet recruiting
Innovent Biologics (Suzhou) Co. Ltd.Industry
NCT07836660 · 198 participants (planned) · Start Oct 15, 2026 · Primary completion Nov 1, 2027
Drug: Part A - Placebo for IBI355; Part B -Telitacicept and 2 more · For: Sjögren's Disease
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy and safety of allogeneic CD19 CAR NK-cell therapy in systemic lupus erythematosus: a case series in China.
Gao J, Li M, Sun M, et al. · Lancet 2026
- Efficacy of telitacicept on renal outcomes in patients with biopsy-proven lupus nephritis: a 12-month follow-up pilot study.
Zhang T, Wang Z, Jiang J, et al. · Int Urol Nephrol 2026
- Research on the safety and efficacy of telitacicept in the treatment of IgA nephropathy in children.
Ying L, Yue X, Zhi C, et al. · Ren Fail 2026
- Perioperative B-Cell-Targeted Therapy for High-Risk Valve Surgery in Active Primary Sjögren's Disease.
Li B, Pan L, Liao H · JACC Case Rep 2026
- Humanistic Burden of Sjögren's Disease: A Systematic Review of Treatment Efficacy on Health-Related Quality of Life.
Akpek EK, Adamson E, Shea L, et al. · Rheumatol Ther 2026
- Update on biologics in SLE.
Delai M, Kyttaris VC · Curr Opin Rheumatol 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.